Chargement en cours...
SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fil...
Enregistré dans:
| Publié dans: | Breast Cancer (Dove Med Press) |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5479299/ https://ncbi.nlm.nih.gov/pubmed/28670138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S131038 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|